Evoke Pharma, Inc. (EVOK) Forms $2.37 Double Bottom; Private Capital Management Lowered Its Visteon Corp. (VC) Stake

February 9, 2018 - By Martha Paddon

Evoke Pharma, Inc. (EVOK) formed double bottom with $2.28 target or 4.00% below today’s $2.37 share price. Evoke Pharma, Inc. (EVOK) has $36.60 million valuation. The stock decreased 3.09% or $0.08 during the last trading session, reaching $2.37. About 22,404 shares traded. Evoke Pharma, Inc. (NASDAQ:EVOK) has declined 51.99% since February 9, 2017 and is downtrending. It has underperformed by 68.69% the S&P500.

Private Capital Management Llc decreased Visteon Corp. (VC) stake by 4.45% reported in 2017Q3 SEC filing. Private Capital Management Llc sold 15,585 shares as Visteon Corp. (VC)’s stock rose 9.26%. The Private Capital Management Llc holds 334,292 shares with $41.38 million value, down from 349,877 last quarter. Visteon Corp. now has $3.62 billion valuation. The stock decreased 2.93% or $3.51 during the last trading session, reaching $116.37. About 84,489 shares traded. Visteon Corporation (NYSE:VC) has risen 41.15% since February 9, 2017 and is uptrending. It has outperformed by 24.45% the S&P500.

Among 18 analysts covering Visteon (NYSE:VC), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Visteon had 53 analyst reports since August 28, 2015 according to SRatingsIntel. The stock of Visteon Corporation (NASDAQ:VC) has “Market Perform” rating given on Thursday, September 17 by Wells Fargo. The firm has “Equal-Weight” rating given on Monday, April 24 by Morgan Stanley. FBR Capital maintained the stock with “Outperform” rating in Wednesday, January 18 report. Morgan Stanley maintained the shares of VC in report on Thursday, January 25 with “Overweight” rating. The firm has “Outperform” rating by FBR Capital given on Friday, April 29. Gabelli downgraded the stock to “Hold” rating in Friday, July 28 report. As per Friday, October 20, the company rating was maintained by Barclays Capital. JP Morgan maintained Visteon Corporation (NASDAQ:VC) on Tuesday, April 19 with “Overweight” rating. Morgan Stanley upgraded the stock to “Overweight” rating in Friday, May 12 report. The stock of Visteon Corporation (NASDAQ:VC) earned “Hold” rating by RBC Capital Markets on Sunday, July 23.

Analysts await Visteon Corporation (NASDAQ:VC) to report earnings on February, 22. They expect $1.70 EPS, down 6.59% or $0.12 from last year’s $1.82 per share. VC’s profit will be $52.87 million for 17.11 P/E if the $1.70 EPS becomes a reality. After $1.42 actual EPS reported by Visteon Corporation for the previous quarter, Wall Street now forecasts 19.72% EPS growth.

Since August 22, 2017, it had 0 insider purchases, and 7 selling transactions for $1.88 million activity. Another trade for 2,004 shares valued at $248,296 was sold by Lawande Sachin. $155,188 worth of Visteon Corporation (NASDAQ:VC) was sold by Cole Matthew M on Tuesday, August 22. $61,307 worth of Visteon Corporation (NASDAQ:VC) was sold by Marianos Stephanie S on Friday, September 15. On Tuesday, September 19 Vallance Robert R sold $133,959 worth of Visteon Corporation (NASDAQ:VC) or 1,106 shares.

Investors sentiment increased to 1.11 in Q3 2017. Its up 0.14, from 0.97 in 2017Q2. It increased, as 22 investors sold VC shares while 83 reduced holdings. 40 funds opened positions while 77 raised stakes. 28.74 million shares or 6.57% less from 30.76 million shares in 2017Q2 were reported. Paradigm Capital Mgmt Incorporated reported 9,500 shares stake. Northern accumulated 206,353 shares. Cookson Peirce & holds 0.85% or 66,060 shares in its portfolio. 5,736 were reported by Quantbot Techs Ltd Partnership. State Of Tennessee Treasury Department stated it has 0.03% of its portfolio in Visteon Corporation (NASDAQ:VC). Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 1,232 shares. Verition Fund Mgmt Ltd Liability Corporation holds 0.05% or 5,370 shares in its portfolio. Boothbay Fund Mngmt Limited Liability Corp, New York-based fund reported 5,648 shares. Neuberger Berman Group Ltd Liability holds 0.01% of its portfolio in Visteon Corporation (NASDAQ:VC) for 85,783 shares. Insight Rech And Management holds 1.23% of its portfolio in Visteon Corporation (NASDAQ:VC) for 17,547 shares. Alliancebernstein Limited Partnership reported 0.01% of its portfolio in Visteon Corporation (NASDAQ:VC). Hillsdale Mngmt Inc reported 0.06% in Visteon Corporation (NASDAQ:VC). Next Financial Gru Incorporated owns 2 shares. Peak6 Invs Ltd Partnership holds 0.01% or 8,542 shares in its portfolio. Comerica Bancorp invested in 11,249 shares.

Analysts await Evoke Pharma, Inc. (NASDAQ:EVOK) to report earnings on March, 21. They expect $-0.22 earnings per share, down 22.22% or $0.04 from last year’s $-0.18 per share. After $-0.24 actual earnings per share reported by Evoke Pharma, Inc. for the previous quarter, Wall Street now forecasts -8.33% EPS growth.

Investors sentiment increased to 4.5 in Q3 2017. Its up 3.00, from 1.5 in 2017Q2. It improved, as 2 investors sold Evoke Pharma, Inc. shares while 0 reduced holdings. 4 funds opened positions while 5 raised stakes. 4.20 million shares or 123.21% more from 1.88 million shares in 2017Q2 were reported. Utd Capital Fincl Advisers Limited Liability owns 15,566 shares for 0% of their portfolio. State Treasurer State Of Michigan stated it has 400,000 shares or 0.01% of all its holdings. Pnc Fincl Services Group holds 0% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK) for 18,000 shares. Pennsylvania-based Vanguard Gru Inc has invested 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). 500 are held by Citigroup. Two Sigma Ltd stated it has 11,137 shares. Knoll Capital Management L P holds 0.64% or 225,000 shares. Blackrock invested in 0% or 62,369 shares. Family Mngmt invested 0.02% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK). Geode Cap Ltd Com, Massachusetts-based fund reported 23,048 shares. Virtu Fin Limited Liability holds 0% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK) for 39,489 shares. Comml Bank Of Ny Mellon Corp holds 24,908 shares or 0% of its portfolio. Bankshares Of America Corporation De has invested 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). Morgan Stanley accumulated 0% or 5,950 shares. Millennium Management Limited Liability Company reported 0% stake.